Latest Press Releases

KFSHRC Successfully Treats Severe Case of "Xanthoma" After 26 Years of Suffering

JEDDAH, Saudi Arabia, June 02, 2024 (GLOBE NEWSWIRE) -- In an era where healthcare innovation is paramount, KFSHRC Jeddah has made headway in the treatment of severe Xanthoma through the deployment of a modified plasma exchange protocol. ...

IHH Reports Highest Ever Quarterly Revenue in Q1 2024, With Double-digit Growth Across Key Metrics, on Outstanding Performance Across All Markets

KUALA LUMPUR, Malaysia and SINGAPORE, May 29, 2024 (GLOBE NEWSWIRE) -- Revenue at RM6.0 billion mark for the first time Outstanding growth momentum: revenue up 16%, EBITDA up 19% Core profit or PATMI (ex EI) up 22%; Lower headline ...

Casey House Creates Fictitious Drug, Stigmavir, to Smash HIV Stigma Within the Health Care System

TORONTO, May 29, 2024 (GLOBE NEWSWIRE) -- Casey House – a hospital unlike any other providing care to those living with and at risk of HIV – today announces the launch of its latest advocacy campaign, Stigmavir. This initiative aims to ...

Global Leaders Gather to Exchange Best Practices in Liver Health Policy

Geneva, Switzerland, May 29, 2024 (GLOBE NEWSWIRE) -- Global Liver Institute (GLI) convened esteemed global leaders for an event on the sidelines of the 77th World Health Assembly in Geneva, Switzerland, entitled “Together for Better Liver ...

Numab Therapeutics Announces Johnson & Johnson to Acquire its Wholly-Owned Subsidiary Yellow Jersey Therapeutics Including Rights to NM26, a Bi-Specific Antibody for the Treatment of Atopic Dermatitis

J&J will gain full rights to develop, manufacture and commercialize NM26 globally for the treatment of atopic dermatitis and follow-on indications Under the agreement terms, J&J will pay $1.25 billion to acquire Yellow Jersey Therapeutics, ...

Switching to Sanofi's Toujeo® Showed Significant Reductions in Blood Sugar and Significantly Lower Incidence of Hypoglycemia in a Real-World Observational Study

- DELIVER 2 Data Showed Reduction in Hypoglycemic Events Related to Inpatient or Emergency Department Visits - PARIS , April 2, 2017 /PRNewswire/ -- Sanofi announced today the presentation of a new observational study 1 in real-world ...

Once-weekly Semaglutide Demonstrated Consistent Blood Glucose Reductions and Weight Loss Regardless of Background Oral Antidiabetic Treatment

ORLANDO, Florida , April 2, 2017 /PRNewswire/ -- Abstract #620 Findings from a post hoc analysis of the phase 3a SUSTAIN 2-4 trials demonstrated greater mean reductions in HbA 1c and body weight with once-weekly semaglutide treatment ...

Updated Phase 1 Data for IPI-549 Presented at AACR Annual Meeting 2017

- IPI-549 Was Well Tolerated as a Monotherapy and in Combination with Opdivo® in Patients with Advanced Solid Tumors - WASHINGTON , April 1, 2017 /PRNewswire/ -- Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) today reported updated Phase 1 ...

Press Releases

Premium Press Releases »

KFSHRC Successfully Treats Severe Case of "Xanthoma" After 26 Years of Suffering

IHH Reports Highest Ever Quarterly Revenue in Q1 2024, With Double-digit Growth Across Key Metrics, on Outstanding Performance Across All Markets

Casey House Creates Fictitious Drug, Stigmavir, to Smash HIV Stigma Within the Health Care System

Global Leaders Gather to Exchange Best Practices in Liver Health Policy

Numab Therapeutics Announces Johnson & Johnson to Acquire its Wholly-Owned Subsidiary Yellow Jersey Therapeutics Including Rights to NM26, a Bi-Specific Antibody for the Treatment of Atopic Dermatitis

Press Releases »

Switching to Sanofi's Toujeo® Showed Significant Reductions in Blood Sugar and Significantly Lower Incidence of Hypoglycemia in a Real-World Observational Study

Once-weekly Semaglutide Demonstrated Consistent Blood Glucose Reductions and Weight Loss Regardless of Background Oral Antidiabetic Treatment

Updated Phase 1 Data for IPI-549 Presented at AACR Annual Meeting 2017

Medindia Newsletters